Funding Opportunity RFA-DK-21-013 from the NIH Guide for Grants and Contracts. This FOA invites applications for continuation of the Collaborative Islet Transplantation Registry? (CITR). Since 2001, this Registry has compiled and analyzed islet transplantation data with the intent to capture all clinical activity in North America as well as additional sites in other countries. Currently, data on both allo- and autotransplantation are collected. The registry will collect data and develop and maintain sophisticated databases to be used by the research community for publications? and presentations. CITR will also prepare an annual report available to the public summarizing outcomes of islet transplantation and trends over time as well as conduct an annual CITR meeting for contributing sites. Collection and analysis of this information? will contribute to identifying risk factors and key safety and efficacy determinants of successful? therapy ofislet transplantation as atreatment for patients with type 1 diabetes and pancreatectomy.

Notice NOT-AA-21-040 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-22-021 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support hypothesis-driven research to gain an understanding of the dysregulation of transposable elements (TE) and their contributions to Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and aging. This FOA encourages applications that investigate causal effects of TE activation in disease and aging and applications that model therapeutic interventions to facilitate the transition of the field from observational discovery towards a deeper mechanistic understanding of the function and regulation of TEs.

Notice NOT-EB-21-021 from the NIH Guide for Grants and Contracts

Notice NOT-AA-21-039 from the NIH Guide for Grants and Contracts

Notice NOT-EB-21-022 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-315 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-21-205 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-19-400. This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, is one of several FOAs aimed at supporting transformative discoveries that will lead to breakthroughs in understanding human brain function. Guided by the long-term scientific plan, BRAIN 2025: A Scientific Vision, this FOA specifically seeks to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. The hope is that efforts supported under this FOA might be both complementary and integrative with the transformative, breakthrough neuroscience discoveries supported through the BRAIN Initiative.

Notice NOT-OD-21-151 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-021 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HL-22-014 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seeks highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications submitted in response to this bi-phasic, milestone-driven cooperative agreement FOA are expected to propose highly innovative projects with a focus on solutions to widely-recognized issues in the development of safe and effective RM therapies. Of particular interest are projects using RM products that have undergone appropriate product development and pre-clinical studies and have demonstrated readiness to advance into clinical trials. This FOA seeks Phase I and beyond clinical trial applications that present a strong scientific rationale for the proposed clinical trial and a comprehensive scientific and operational plan. Trials must be relevant to the research mission of one or more participating NIH Institutes and Centers and meet the NIH definition of a clinical trial (see NOT-OD-15-015). Applications are expected to include plans for project management, participant recruitment and retention, performance milestones, conduct of the trial, and dissemination of results. Before the time of award and if applicable, successful applicants must obtain an Investigational New Drug (IND) authorization or Investigational New Device Exemption (IDE) approval to administer the product to humans. Successful applicants proposing the use of adult stem cells as a clinical intervention will be asked to make available representative samples of the source stem cell and clinical-grade stem cell-derived product for in-depth and independ

Notice NOT-HS-21-017 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-21-025 from the NIH Guide for Grants and Contracts. The purpose of the FIRST Cohort is to transform culture at NIH-funded extramural institutions by building a self-reinforcing community of scientists committed to diversity and inclusive excellence (defined below). Implementing and sustaining cultures of inclusive excellence within the program has the potential to be transformational for biomedical research at the awardee institutions and beyond. This community will be built through recruitment of faculty who are competitive for an advertised research tenure-track or equivalent faculty position (positions must be at the Assistant Professor (or equivalent) level), have not held a position at this level, and have demonstrated strong commitment to promoting diversity and inclusive excellence.

Funding Opportunity RFA-LM-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement (U24) applications for the Network of the National Library of Medicine (NNLM) All of Us Program Center (NACP). The mission of the NNLM is to provide U.S. health professionals, researchers, public health workforce, educators, and the public with equal access to biomedical and health information resources and data. NNLMs main goals are to work through libraries and other members to support a highly-trained workforce for biomedical and health information resources and data, improve health literacy, and increase health equity through information. The NNLM All of Us National Program Center (NAPC) will serve as the coordinating center and be responsible for the engagement, programs, partnerships, activities, and training offered by NNLM in support of the NIH All of Us Research Program. All of Us is working to improve health care through research by building a diverse database that can inform thousands of studies on a variety of health conditions. The NACP will continue to improve and innovate in two main functional areas: Training and Education, and Community Engagement. These two functional areas collaborate, coordinate, and cooperate to design, deliver, report, and evaluate innovative, responsive, and effective programs and services. They also work together to increase awareness about the NIH All of Us Research Program and to improve the health, digital, and related literacy skills that allow the general public to participate in long-term clinical research programs.

Funding Opportunity PAR-21-247 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.

Funding Opportunity PAR-21-274 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support the program "Cancer Target Discovery and Development (CTD2, pronounced cee-tee-dee-squared). CTD2 is focused on efforts that advance cancer research by bridging the knowledge gap between the large volumes of comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis. The primary purpose of CTD2 is to advance the following areas: Improving the understanding of how mutations in cancer-associated genes affect the protein activity (e.g., gain-of-function, loss-of-function, or neomorphic function) within the cellular pathway(s) they are part of and the cellular changes that result within the context of various tumors and the microenvironment; Identifying new molecular targets with the goal to understand their wiring mechanisms and how overcome innate and/or acquired resistance to therapies, particularly clinical resistance related to inter- and intra- tumor heterogeneity; and Developing efficient strategies to identify appropriate multiple targets and optimal combination of perturbagens (chemical or biological; immunotherapeutics being a prime example of the latter) with the potential to eliminate all cancer cells, despite their clonal heterogeneity and their surrounding microenvironment.

Funding Opportunity PAR-21-248 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune systemdevelopment patterns between two or more age groups- neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on ontogeny and development of pediatric immune system, from birth, transitioning into adolescence and adulthood with focus impact during pregnancy and post-natal period.

Funding Opportunity PAR-21-281 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites basic and/or methodological research projects that seek to illuminate or measure independent and interdependent health-related effects within dyads. For the purpose of this FOA, a dyad is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Both animal and human subjects research projects are welcome. Types of projects submitted under this FOA include but are not limited to, studies observational studies involving humans, or existing/synthesized datasets studies. Applications proposing studies that prospectively assign human participants to conditions meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024). Researchers proposing basic science experimental studies involving human participants (i.e., experimentally manipulate independent variables) should consider the companion FOA PAR-XX-XXX "Dyadic Interpersonal Processes and Biopsychosocial outcomes (R01 Basic Experimental Studies with Humans).

Funding Opportunity PAR-21-280 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites basic and/or methodological research projects that seek to illuminate or measure independent and interdependent health-related effects within dyads. For the purpose of this FOA, a dyad is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects that emanate from intra-dyadic phenomena. NIH considers such studies as prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024). Applications proposing studies using model animal research, observational studies involving humans, or existing/synthesized datasets should submit under the companion FOA PAR-XX-XXX " Dyadic interpersonal processes and biopsychosocial outcomes (R01 Clinical Trials Not Allowed).

Funding Opportunity RFA-HG-21-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.